Introduction
The major problem in cancer therapy by cytokines and chemotherapeutic agents is the development of resistance to apoptosis (Baldini, 1997) , the mechanisms for which are not fully understood. Inactivation of p53 and related proteins, or expression of p-glycoprotein, Bcl-2, glutathione S-transferase, protein kinase C, transglutaminase, and heat shock proteins (e.g. hsp 27) has each been suggested to play an important role in resistance to anticancer agents (Bellamy and Dalton, 1994; Harrison, 1995; Reed, 1995) . The activated form of NF-kB has also recently been implicated in the development of resistance to TNF (Beg and Baltimore, 1996; Van Antwerp et al., 1996; Wang et al., 1996; Giri and Aggarwal, 1998; .
NF-kB, a nuclear transcription factor, was first identified by Sen and Baltimore (1986) . It regulates the expression of various gene products such as various adhesion molecules (ICAM-1, VCAM-1, ELAM-1), cyclooxygenase-2, and matrix metalloprotease-9, which play critical roles in inflammation, viral replication, tumor initiation, tumor promotion, metastasis, and apoptosis (Collins et al., 1995; Roshak et al., 1996; Baeuerle and Baichwal, 1997; Baichwal and Baeuerle, 1997; Lee and Burckart, 1998; Wang et al., 1999b; Waddick and Uckun, 1999) . As part of the stress response, NF-kB is activated in response to various inflammatory stimuli including cytokines, mitogens, bacterial products, viral proteins, and apoptosis-inducing agents; consequently, this factor is currently a target of pharmaceutical interest (Lee and Burckart, 1998) . NF-kB is also an ideal target for anticancer drug development, as it has been shown to block apoptosis and to promote proliferation (Van Antwerp, 1996; Wang et al., 1996 Wang et al., , 1998 . NF-kB activation induces resistance to chemotherapeutic agents (Wang et al., 1999a, b) and constitutive expression of NF-kB induces proliferation of tumor cells (Nakshatri et al., 1997; Giri and Aggarwal, 1998) .
NF-kB is a heterodimer of two subunits p50 (NFkB1) and p65 (RelA) , that is normally present in the cytoplasm in an inactive state in complex with an inhibitory subunit of kappa B (IkBa). Upon phosphorylation and subsequent degradation of IkBa, a nuclear localization signal on the p50-p65 heterodimer is exposed, leading to nuclear translocation of NF-kB. The p50-p65 heterodimer binds with a specific sequence in DNA, which in turn results in gene transcription. Phosphorylation of p65 of NF-kB (RelA) is required for effective NF-kB-dependent gene transcription (Egan et al., 1999) . In this study, time course-dependent increase or decrease in NF-kB levels in nuclear extracts has been referred to as upregulation or downregulation of NF-kB, respectively. Interestingly, several chemotherapeutic agents such as doxorubicin and daunorubicin (Boland et al., 1997; Das and White, 1997), taxol, vinblastine and vincristine (Das and White, 1997) , camptothecin (Piret and Piette, 1996) , and etoposide (Perez, 1997 ) also cause NF-kB upregulation.
Constitutive upregulation of NF-kB has recently been correlated with progression of breast cancer, melanoma, and juvenile myelomonocytic leukemia (Kochetkova et al., 1997; Nakshatri et al., 1997; Raziuddin et al., 1997; Izban et al., 2000) . How NF-kB is constitutively up-regulated in some tumor cells and what role it plays in acquiring resistance to apoptosis is not clear. It has been shown that HuT-78, a cutaneous lymphoid T-cell line that constitutively expresses NF-kB, is resistant to the apoptotic effects induced by TNF . In T cells, NF-kB also activates the expression of Bcl-2, an antiapoptotic factor (Heckman et al., 2002) . On the other hand, in endothelial cells, Bcl-2 and Bcl-XL have been shown to inhibit NF-kBmediated gene transcription, by inhibiting IkBa degradation (Badrichani et al., 1999) .
Resistance to chemotherapy is a major problem in the treatment of cancers. Combination therapy may be a useful tool in this regard, and it has been shown that a combination of thalidomide plus dexamethasone is effective in myeloma (Rajkumar et al., 2002) , while the combination of dacarbazine, nimustine hydrochloride, vincristine sulfate, and interferon-b is useful in anorectal melanoma (Terada et al., 2002) .
Cytosine arabinoside (araC) has been shown to induce apoptosis through various mechanisms. AraC and its different metabolites contribute to its cytotoxicity including incorporation of AraCTP into DNA and AraUMP into RNA, inhibition of polymerase a and b, and impairment of repair mechanisms (Braess et al., 1999) . Besides this DNA synthesis impairment, araC engages an array of signaling events, including activation of PKC and MAPK (Kharbanda et al., 1994) and upregulation of AP-1 and NF-kB (Brach et al., 1992a,b) . Simultaneous activation of both pathways for apoptosis by impairing DNA repair and for survival by inducing antiapoptotic influence of MAPK mediated by araC are interesting. In this study, we have examined the effect of the anticancer agent araC on apoptosis in cells expressing NF-kB.
As NF-kB is currently being used as a target for cancer therapy, it is important to understand the possible interplay of NF-kB and drug resistance. In this study, we demonstrate, for the first time, that araC mediates apoptosis in NF-kB-expressing cells, HuT-78 and SA-LPS/Jkt cells. In these cells, araC downregulates NF-kB by activation of phosphatases that dephosphorylate its p65 subunit. We also demonstrate the sensitivity of araC in NF-kB expressed cells treated with different anticancer agents.
Results
In the present report, we investigated the role of NF-kB in apoptosis induced by TNF, araC, or ceramide in two human T-cell lines, Jurkat and HuT-78. HuT-78 cells constitutively express the nuclear transcription factor NF-kB. In Jurkat cells, NF-kB expression was induced with serum-activated lipopolysaccharide, as described in Materials and methods.
AraC downregulates NF-kB activation in Jurkat cells
To investigate the effects of TNF, araC, or ceramide on the levels of NF-kB, Jurkat cells (1 Â 10 6 /ml) were incubated with 1 nm TNF, 50 mm araC, or 10 mm ceramide for different times at 371C. NF-kB activity in nuclear extracts was determined by electrophoretic mobility shift assay (EMSA) as indicated in Materials and methods using 32 P-labeled oligonucleotide carrying NF-kB binding sequence. As shown in Figure 1a , TNF and ceramide treatments led to persistent induction of NF-kB activity, whereas araC treatment was associated with an initial increase in NF-kB activity in 2 h followed by complete loss of NF-kB activity at and beyond 4 h. In control experiments, the levels of Oct1, a house-keeping transcription factor, were assayed and shown to be roughly the same in all the samples (Figure 1b) .
Of the various possible oligomeric combinations of p50 and p65 (i.e., p50-p50 or p65-p65 homodimer, or p50-p65 heterodimer) NF-kB is able to bind to specific sequences in DNA. To show that the retarded band visualized by EMSA in araC-treated cells was indeed NF-kB, we incubated the nuclear extracts from ceramide-activated cells with antibodies (Abs) to p50 and p65 alone or in combination, and then conducted EMSA. Abs to either subunit of NF-kB shifted the band to a higher m.w. (Figure 1c ), thus suggesting that the araC-activated complex consisted of both p50 and p65 subunits. Neither preimmune serum nor irrelevant Abs such as anti-c-Rel or anticyclin D1 had any effect on the mobility of NF-kB. The complex completely disappeared in the presence of a 50-fold molar excess of cold NF-kB indicating its specificity as that of NF-kB.
AraC downregulates IkBa level in Jurkat cells
The translocation of NF-kB to the nucleus is preceded by the phosphorylation and proteolytic degradation of IkBa. To test the roles of TNF, araC, or ceramide on IkBa levels, the cytoplasmic extracts from the experiment described in the previous section were examined by Western blot analysis. Upon treatment with TNF or ceramide, the levels of IkBa showed an initial decline followed by slow recovery up to 24 h; in the case of TNF, the levels again declined from 12 h. With araC treatment, the IkBa level showed a sustained decrease up to 24 h (Figure 1d) . We interpret the changes in IkBa levels as being the consequence (rather than the cause) of changes in NF-kB. Upon re-probing, all these gels with anti-p50 antibody, we found that the band intensities in all the lanes were uniform, indicating equal loading of extracted protein in the lanes. These results indicate that in TNF-or ceramide-treated cells, first there is degradation of IkBa leading to upregulation of NF-kB, and then resynthesis of IkBa since the latter is itself an NF-kB-dependent gene product. TNF-induced IkBa degradation at later time points may be because of the availability of TNF in the medium as we stimulated cells with 1 nm TNF and it is very stable in aqueous phase. AraC-mediated downregulation of NF-kB correlates with the degradation of IkBa without resynthesis.
AraC inhibits NF-kB activation in SA-LPS/Jkt and HuT-78 cells Jurkat, SA-LPS-stimulated Jurkat, or HuT-78 cells (2 Â 10 6 /ml each) were incubated with different concentrations of TNF, araC, or ceramide for 4 h at 371C. Nuclear extracts were prepared and assayed for NF-kB by EMSA. As shown in Figure 2 , all these agents induced NF-kB activation in Jurkat cells. SA-LPS/Jkt cells showed sustain levels of upregulated NF-kB and HuT-78 cells showed basal levels of NF-kB upregulation, which were marginally activated by TNF or ceramide. On the other hand, araC suppressed NF-kB in SA-LPS/Jkt and HuT-78 cells, as evidenced from the disappearance of the shifted band in the corresponding nuclear extracts. All the lanes exhibited equivalent intensities of Oct1, assayed as the loading control.
AraC, but not TNF or ceramide, inhibits NF-kB reporter gene expression in SA-LPS/Jkt and HuT-78 cells Jurkat, SA-LPS/Jkt, and HuT-78 cells were each transfected with a construct expressing NF-kB-SEAP (secretory alkaline phosphatase) reporter gene fusion and dominant-negative IkBa. The cells were aliquoted, cultured for 24 h, and stimulated with different /ml) were incubated with TNF (1 nm), araC (50 mm), or ceramide (10 mm) for different times as indicated in the figure. After these treatments, cytoplasmic and nuclear extracts were prepared. Nuclear extracts were assayed for NF-kB (a) and Oct1 (b), as described in Materials and methods. (c) Nuclear extracts were prepared from untreated or araC-treated Jurkat cells, incubated for 15 min with different Abs and cold NF-kB oligo, and then assayed for NF-kB, as described in Materials and methods. /ml) were incubated with different concentrations of TNF, araC, or ceramide for 4 h. After these treatments, nuclear extracts were prepared and then assayed for NF-kB and Oct1 as described in Materials and methods 6 ) cells were treated with araC (50 mm) or TNF (1 nm) for 24 h at 371C in a CO 2 incubator. Then cell extracts were prepared and 50 mg protein was analysed by 7.5% SDS-PAGE to detect PARP by Western blot using anti-PARP mAb. (c) HuT-78 (2 Â 10 6 ) cells were treated with araC (50 mm) and TNF (1 nm) for different times at 371C in a CO 2 incubator. Then cell extracts were prepared and 400 mg protein was immunoprecipitated against anti-Bcl-2 and -CRM1 Ab and analysed by 10% SDS-PAGE to detect Bcl2 by Western blot using anti-Bcl2 Ab. The level of IgG heavy chain was visualized from the same X-ray film. The same blot was reprobed with anti-CRM1 antibody and the level of CRM1 was detected by Western blot analysis. ) were treated with araC (50 mm) or TNF (1 nm) for different times at 371C, extracted proteins were immunoprecipitated with anti-Bcl-2 and -CRM1 Ab and then analysed for Bcl-2 by Western blot. The levels of Bcl-2 almost did not alter in TNF-treated cells but were downregulated in araC-treated cells (Figure 5c ) indicating araC-mediated apoptosis in NF-kB expressed cells. In the same blot, the levels of IgG heavy chain were equal in all these lanes, indicating equal addition of the antibody. The same blot was probed with anti-CRM1 Ab and the levels of CRM1 were equal in each lane indicating loading control. TNF or ceramide enhanced DNA fragmentation in Jurkat, but not in HuT-78 or SA-LPS/Jkt cells, whereas araC induced DNA fragmentation in Jurkat, HuT-78, or SA-LPS/Jkt cells as shown by DNA laddering (Figure 5d ). Propidium iodide (PI)-stained cells also showed nuclear fragmentation ( Figure 5e ).
AraC dephosphorylates p65 in SA-LPS/Jkt and HuT-78 cells
As phosphorylation of the p65 subunit of the NF-kB is required for NF-kB-mediated gene transcription and araC downregulates NF-kB in HuT-78 or SA-LPS/Jkt cells, we tested the role of araC in p65 phosphorylation. Jurkat, HuT-78, or SA-LPS/Jkt cells (5 Â 10 6 ) were incubated with [ 32 P]orthophosphate and treated with TNF, araC, or ceramide for 4 h. Extracts were prepared, immunoprecipitated with anti-p65 antibody and analysed for p65 as described in Materials and methods. In Jurkat cells all these agents induced p65 phosphorylation. The high levels of p65 phosphorylation were shown in HuT-78 or SA-LPS/Jkt cells that were not further induced by TNF or ceramide, whereas araC treatment led to the loss of the p65-phosphorylated band in these cells (Figure 6a, upper panel) . As control for loading artefacts, aliquots of 50 mg proteins from the same extracts were analysed by 9% SDS-PAGE, and bands were shown by chemiluminescence to have equivalent levels of p65 (Figure 6a, lower panel) . The results indicate that araC suppresses the phospho-p65 band of HuT-78 or SA-LPS/Jkt cells.
Calyculin A protects araC-induced downregulation of p65 phosphorylation, NF-kB activation, and cytotoxicity
To understand the mechanism of downregulation of phosphorylated p65, we used calyculin A, a specific serine/threonine phosphatase inhibitor (Suganuma et al., 1990) , and ZnCl 2 , a protein-tyrosine phosphatase inhibitor (Tonks et al., 1991) , to investigate the mechanism of araC-induced signaling (cytotoxicity, p65 phosphorylation, and NF-kB activation) in NFkB expressed cells. HuT-78 or SA-LPS/Jkt cells were pretreated with calyculin A or ZnCl 2 and then treated with different concentrations of araC for 72 h, following which cytotoxicity was assayed by MTT. The results indicate that calyculin A, but not ZnCl 2 protects HuT-78 or SA-LPS/Jkt cells from araC-induced cell killing (Figure 6b ).
HuT-78 or SA-LPS/Jkt cells were incubated with [ 32 P]orthophosphate and calyculin A (10 nm) for 4 h and then stimulated with araC (50 mm) for 4 h. The cell extracts were then immunoprecipitated with anti-p65 antibody and analysed for the labeled p65 band. The results shown in Figure 6c indicate that araC mediates the de-phosphorylation of p65 in HuT-78 and SA-LPS/ Jkt cells which in turn is blocked by calyculin A. When calyculin-A-pretreated HuT-78 or SA-LPS/Jkt cells were exposed to araC for 4 h and the nuclear extracts were then assayed for NF-kB, we observed complete protection conferred by calyculin A on araC-mediated downregulation of NF-kB activation in these cells ( Figure 6D ).
AraC induces protein phosphatases 2A and 2B-A, which dephosphorylate p65 in vitro
To detect the phosphatase(s) involved in araC-mediated dephosphorylation of p65, Jurkat cells were stimulated with araC (50 mm) for 2 and 6 h. The cell extracts were immunoprecipitated with antibodies against PP1, PP2A, and PP2B-A and the complexes were incubated with 32 Pp65 for 2 h at 371C as described in Materials and methods. The intensity of the labeled p65 band was decreased in PP2A and PP2B-A with time of incubation but not in the case of PP1 indicating the activation of PP2A and PP2B-A by araC (Figure 6e ). The 80 mg of the extracted protein from the same extracts was analysed in 9% SDS-PAGE and Western blot performed against anti-PP1, -PP2A, and -PP2B-A. The bands showed equal intensity in each case indicating that the level of expression of those phosphatases is not changed with the increased time of araC treatment (Figure 6f) .
To detect the role of araC in p65 (RelA) and PP2A interaction in vitro, equal amounts of 32 P-p65 proteins were incubated with araC and PP2A (immunoprecipitated from 500 mg unstimulated Jurkat cells extract) alone or in combination for 2 h at 371C in microfuge tubes. Then the levels of labeled p65 proteins were analysed. The levels of the labeled p65 band showed equal intensities (Figure 6g ), indicating that araC has no role in the interaction of p65 and PP2A in vitro.
AraC potentiates cis-platin-, etoposide-, or taxolmediated cytotoxicity in SA-LPS/Jkt and HuT-78 cells NF-kB is known as an antiapoptotic factor (Kochetkova et al., 1997; Nakshatri et al., 1997; Raziuddin et al., 1997; Izban et al., 2000) . In order to detect the role of NF-kB on cell viability, HuT-78 or SA-LPS/Jkt cells were incubated with 10 mm each of cis-platin, vincristine, doxorubicin, etoposide, adriamycin, or taxol and 50 mm of araC for 72 h and MTTassayed. As shown in Figure 7a , all those agents decreased cell viability in Jurkat cells. Cis-platin, etoposide, taxol, or araC partially blocked cell viability in HuT-78 or SA-LPS/Jkt cells. We observed that araC downregulated NF-kB in NF-kB expressed cells. ) were incubated with 2 mCi [ 32 P]orthophosphate for 6 h in phosphate-free medium. Cells were treated with TNF (1 nm), araC (50 mm), or ceramide (10 mm) for 4 h and extract was prepared, 500 mg of the extract protein was immunoprecipitated using anti-p65 antibody and analysed in 9% SDS-PAGE for p65 radioactive band. Aliquots of 50 mg proteins from the same extracts were analysed for p65 in 9% SDS-PAGE and bands were detected by Western blot. (b) Effect of calyculin A and ZnCl 2 on araC-induced cytotoxicity. SA-LPS/Jkt and HuT-78 (10
Discussion
The mechanism coupling araC-induced DNA damage to the initiation of cell death have not yet been fully established. Myeloid leukemia cells have been shown to be treated with araC. The mechanism of araC-mediated cell death has been shown by inhibition of mitogenactivated protein kinase (MAPK) and interruption of protein kinase C (Jarvis et al., 1998) . TNF and ceramide have been shown to induce apoptosis in different pathways (Manna and Aggarwal, 2000; Manna et al., 2000a) . To dissect the signaling mechanism induced by different apoptotic inducers, we used TNF, araC, and ceramide as these inducers act through different mechanisms and to understand the role of NF-kB on the mechanism of drug resistance. TNF is a well-known inducer of apoptosis through death domain activation and caspase recruitment (Baker and Reddy, 1998) .
Ceramide, an intermediate messenger molecule induced by a variety of apoptotic inducers including TNF though the mechanism of cell signaling mediated by ceramide differs from TNF (Manna and Aggarwal, 2000; Manna et al., 2000b) . All these inducers follow NF-kB activation as a downstream signal. However surprisingly, when we incubated Jurkat cells with TNF, araC, or ceramide for different time periods it has been shown that NF-kB activation was maintained till 24 h of incubation by TNF and ceramide but not by araC (Figure 1) . To understand the mechanism of araCmediated downregulation of NF-kB, we used HuT-78, constitutively expressed NF-kB cells and endotoxinstimulated Jurkat cells. Serum-activated LPS stimulates Jurkat T cells for induction of NF-kB potently and maintains the level of expression for a long time . LPS interacts with lipopolysaccharide binding protein (LBP) of serum and forms AraC dephosphorylates p65 NF-jB Y Sreenivasan et al LPS-LBP complex (also known as endotoxin) and it acts through CD14 cell surface receptors for cell stimulation. The LPS used for activation in the form of SA-LPS was 100 ng/ml, which is not toxic to cells for a long time as detected by cell viability.
Our results indicate that TNF, araC, or ceramide induced NF-kB in Jurkat cells, but araC, downregulates NF-kB activation after 4 h (Figure 1a) . Ceramide-and TNF-induced NF-kB activation is correlated with IkBa degradation (Figure 1d) . IkBa is an NF-kB-dependent gene product. As TNF or ceramide induces NF-kB, IkBa degradation was observed initially but later it is resynthesized. The TNF-mediated IkBa resynthesis occurred at 2 h but again it degraded at 12 and 24 h time points. Possibly the effect of TNF is long-lasting and presence in the medium exerts its effect further. AraC has been shown to induce IkBa degradation until 24 h. As araC downregulates NF-kB, IkBa, an NF-kBdependent gene, is not resynthesized further. TNFmediated apoptosis was not observed in HuT-78 and serum-activated Jurkat cells, which is consistent with our earlier report . Ceramide-induced apoptosis was also not observed in those NF-kB expressed cells indicating the common AraC has been shown to downregulate NF-kB, as indicated by gel retardation assay (Figure 2 ) and NFkB-dependent reporter gene expression in NF-kB expressed cells (Figure 3 ) indicating a novel mechanism followed by araC. TNF-and ceramide-mediated cell apoptosis was not observed in NF-kB expressed cells, either HuT-78 (constitutively) or SA-LPS/Jkt (induced) cells, as detected by MTT assay (Figure 5a ), PARP cleavage (Figure 5b ), Bcl2 degradation (Figure 5c ), DNA fragmentation (Figure 5d ), and visualized by nuclear fragmentation (Figure 5e ). NF-kB expressed cells showed antiapoptotic activity by inhibiting apoptosis induced by TNF or ceramide. AraC-induced apoptosis was shown in NF-kB expressed cells, indicating a different mechanism of action from that of TNF or ceramide. In NF-kB expressed cells, TNF or ceramide was unable to induce lipid peroxidation as detected by MDA production and ROIs generation as detected by the conversion of dihydrorhodamine to rhodamine and analysed in FACScan, further indicating that the cells are not following the apoptosis pathway. On the other hand, araC-induced lipid peroxidation and ROI generation were observed in NF-kB expressed cells (Figure 4 ). Bcl-2 has been shown to exert an antiapoptotic activity in cells and it is an NF-kB-dependable gene product (Heckman et al., 2002) . Overexpressed Bcl-2 again downregulates NF-kB and dependent gene products (Badrichani et al., 1999) . In this report we provide the evidence that araC downregulates Bcl-2 level in NF-kB expressed cells. As araC downregulates NFkB, it may correlate with the downregulation of NF-kBmediated synthesis of Bcl-2 (Heckman et al., 2002) or araC-mediated apoptotic pathways that may degrade Bcl-2.
As reported previously, araC hypophosphorylated retinoblastoma protein, phosphorylated by cyclin-dependent kinases and stimulates cell cycle in HL-60 cells and later it was proved that araC induced tyrosine phosphatase, which dephosphorylates retinoblastoma protein causing apoptosis (Dou and Lui, 1995; Wang et al., 2001) . As NF-kB is an ideal target for anticancer drug development, it is important to detect its role on araC-mediated cell signaling. An active NF-kB dependent gene expression requires the p65 subunit of NF-kB to be phosphorylated (Egan et al., 1999; Manna et al., 2000a) . We observed that TNF, araC, or ceramide induced p65 phosphorylation (Figure 6a) , which was correlated with NF-kB activation and dependent gene expression. Surprisingly, in NF-kB expressed cells, TNF or ceramide did not interfere with the high level of p65 phosphorylation but araC downregulated the phosphop65 protein level in both NF-kB expressed cells (induced and constitutive) (Figure 6c ). Zinc is believed to be an inhibitor of protein-tyrosine phosphatase inhibitor. AraC-mediated inhibition of NF-kB or apoptosis was not modulated by ZnCl 2 whereas addition of calyculin A completely protected araC-induced inhibition of cytotoxicity ( Figure 6b ) and downregulation of NF-kB (Figure 6d ). AraC activates phospho-serine/phosphothreonine phosphatase, which dephosphorylates the p65 subunit of NF-kB and makes cells more apoptotic. AraC activates PP2A and PP2B-A but not PP1. Activated PP2A and PP2B-A dephosphorylate basal phospho-p65 in NF-kB expressed cells (Figure 6e ) without changing the level of those phosphatases expression (Figure 6f ). AraC does not interfere with the interaction between p65 and PP2A in vitro (Figure 6g) . So, araC has a potential role to make cells sensitive to cell death which attain resistance to apoptosis because of NF-kB. This is the first report that the p65 subunit of NF-kB undergoes dephosphorylation by phosphatases activity induced by araC and cells become sensitive to apoptosis.
Pretreatment of araC and then stimulation of different anticancer agents also shows the potentiation of apoptosis (Figure 7) . Combinatorial therapy is an important aspect in regulating cancer progression and metastasis. As chemotherapeutic agent-induced resistance is the main problem for cancer, the understanding of the basic mechanism will be helpful in addressing this problem. NF-kB expressed cells showed 20-40% cell survival in cis-platin-, etoposide-, adriamycin-, taxol-, or araC-mediated cytotoxicity (Figure 7a ). These agents showed potentiation of cell killing in combination with AraC in NF-kB expressed cells (Figure 7b) .
Overall, our results suggest that dephosphorylation of a key protein, p65, by protein phosphatases may be crucial for the initiation of apoptosis in NF-kB expressed cells, and further support the concept of protein phosphatase serving as a potential target for anticancer therapy. Our studies suggest that the dephosphorylation of the p65 subunit of NF-kB might be an important strategy for treating drug-resistant cancers.
Materials and methods

Materials
AraC, C2 ceramide (N-acetyl-d-sphingosine), MTT [3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide)], glycine, calyculin A, ZnCl 2 , doxorubicin, vincristine, taxol, cis-platin, etoposide, adriamycin, and LPS (Escherichia coli, 055:B5) were obtained from Sigma (St Louis, MO, USA). Penicillin, streptomycin, RPMI-1640 medium, and fetal bovine serum (FBS) were obtained from Life Technologies (Grand Island, NY, USA). TNF was obtained from PeproTech Inc., NJ, USA. Dihydrorhodamine was purchased from Molecular Probe, The Netherlands. Oct1 double-stranded oligonucleotide and antibodies (Abs) against PP1, PP2A, PP2B-A, IkBa, p50, p65, cyclin D1, c-Rel, CRM1, and Bcl2 were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Poly ADP-ribose polymerase (PARP) antibody (Ab) was purchased from PharMingen (San Diego, CA, USA).
Cell lines
Jurkat and HuT-78 (T cells) cells, obtained from American Type Culture Collection (Manassas, VA, USA), were cultured in RPMI-1640 medium supplemented with 10% FCS, penicillin (100 U/ml), and streptomycin (100 mg/ml) and were mycoplasma free, as tested by Gen-probe mycoplasma rapid detection kit (Fisher Scientific, Pittsburgh, PA, USA) as described (Giri and Aggarwal, 1998; .
HuT-78 cells constitutively express the nuclear transcription factor NF-kB. In Jurkat cells, NF-kB expression was induced with serum-activated lipopolysaccharide (100 ng LPS was incubated with 20 ml of rabbit serum for 1 h at 371C to make SA-LPS and this was used for treatment) for 24 h at 371C to upregulate NF-kB. The concentration used for LPS activation did not show any cytotoxicity, as detected by MTT assay, up to 72 h (cell viability was 98.02 73.24, 96.3473.36, 94.7873.24, 91.4274.48, and 92.2475.52 at 0, 24, 36, 48 , and 72 h of incubation, respectively).
NF-kB activation assay
NF-kB activation was assayed following the method described (Manna et al., 1998) . Nuclear extract (8 mg protein) was incubated with 4 ng of 32 P end-labeled 45-mer double-stranded NF-kB oligonucleotide from the HIV-LTR, 5 0 -TTG TTA CAA GGG ACT TTC CGC TGG GGA CTT TCC AGG GAG GCG TGG-3 0 (bold indicates NF-kB binding site) and assayed for NF-kB using 6.6% native PAGE by EMSA. Similarly, 8 mg nuclear extract protein was incubated with 32 Plabeled double-stranded Oct1 oligonucleotide and assayed in 6% native PAGE by gel retardation assay.
Cytotoxicity assay
The cytotoxicity was measured by MTT assay (Manna et al., 1998) . Briefly, cells (1 Â 10 4 cells/well of 96-well plate) were treated with inducers for 72 h and thereafter, 25 ml of MTT solution (5 mg/ml in phosphate buffer saline (PBS)) was added to each well. After a 2-h incubation at 371C, 0.1 ml of the extraction buffer (20% SDS, 50% dimethylformamide) was added. After an overnight incubation at 371C, the absorbance was read at 570 nm.
Western blot of PARP and Bcl-2
Apoptosis was examined by the proteolytic cleavage of PARP (Manna et al., 1998) . Briefly, cells were treated with different inducers and whole-cell extracts were prepared. Cell extract protein (50 mg) was resolved on 7.5% SDS-PAGE, electrotransferred onto a nitrocellulose membrane, blotted with mouse anti-PARP Ab, and then detected by chemiluminescence (Amersham Pharmacia Biotech, Piscataway, NJ). Apoptosis was represented by the cleavage of 116-kDa PARP into an 85-kDa product (Manna et al., 1998; . TNF-and araC-treated HuT-78 cell extracts were immunoprecipitated with anti-Bcl-2 and -CRM1 (nuclear export receptor protein) Ab. Then the blot was used to detect Bcl-2 and CRM1 levels by Western blot analysis.
NF-kB-dependent reporter gene transcription
The effect of different inducers of apoptosis on NF-kBdependent reporter gene transcription was measured as previously described (Darnay et al., 1999) . Briefly, cells were transiently transfected by the calcium phosphate method with 1 ml medium containing 0.5 mg NF-kB promoter DNA linked to the heat-stable SEAP gene. After 24 h of culture, cells were stimulated with TNF, araC, and ceramide for 6 h and then the culture-conditioned medium was harvested, and 25 ml was analysed for alkaline phosphatase activity using 4-methylumbelliferyl phosphate as substrate essentially as per the CLONTECH protocol (Palo Alto, CA, USA). This reporter system was specific, because ceramide-induced NF-kB SEAP activity was inhibited by overexpression of IkBa mutants lacking either Ser 32 or Ser 36 .
Determination of lipid peroxidation and measurement of ROIs
Lipid peroxidation was determined by detection of thiobarbituric acid-reactive MDA, an end product of the peroxidation of polyunsaturated fatty acids and related esters as described (Bowie et al., 1997; Manna et al., 2000a) . The production of ROIs was determined by flow cytometry as described . Treated or untreated cells were exposed to dihydrorhodamine 123 and then washed with PBS. Rhodamine 123 fluorescence intensity resulting from dihydrorhodamine 123 oxidation was measured by a FACScan flow cytometer (Becton Dickinson, Mountain View, CA, USA) with excitation at 488 nm and was detected between 515 and 550 nm. Data analysis was performed using LYSYSII software (Becton Dickinson).
Determination of DNA and nuclear fragmentation DNA was extracted with phenol : chloroform : isoamyl alcohol (25 : 24 : 1, v/v/v) and precipitated by 100% ethanol at À201C overnight (Ito et al., 1999) and ran on 1% agarose gel. DNA fragments were visualized as ladder with ethidium bromide under UV light. After treatment, cells were fixed in 80% methanol overnight at 41C and pellets were suspended in 100 ml of PI mixture for 30 min. Cells were then viewed under a fluorescence microscope to determine nuclear fragmentation (Nutku et al., 2001 ).
Immunoprecipitation of p65 from orthophosphate-labeled cells
To determine the phosphorylation of the p65 subunit of NFkB (Manna et al., 2000a) , Jurkat, HuT-78, and SA-LPS stimulated Jurkat cells (5 Â 10 6 ) were labeled with [ 32 P]orthophosphate (Amersham) in phosphate-free medium for 4 h at 371C, and then the cells were treated with TNF (1 nm), araC (50 mm), and ceramide (10 mm) for 4 h at 371C. Then the cellextracted proteins were immunoprecipitated with anti-p65 polyclonal Ab (Santa Cruz Biotechnology) followed by protein A/G sepharose beads. Washed beads were then boiled with SDS sample buffer for 5 min, and subjected to SDS-PAGE (9%). The gel was dried, exposed to PhosphorImager screen, and analysed by a PhosphorImager (Fuji, Japan). To confirm equal loading, 50 mg protein was resolved on 10% SDS-PAGE, electrotransferred to nitrocellulose filters, and probed with the anti-p65 Ab, and the bands were detected by chemiluminescence (ECL, Amersham).
In-vitro phosphatases activity assay
Jurkat cells (5 Â 10 6 ), labeled with [ 32 P]orthophosphate (Amersham) in phosphate-free medium for 4 h at 371C, were stimulated with TNF (1 nm) for 1 h. Cell extract proteins were incubated with anti-p65 antibody followed by immunoprecipitation with protein A/G sepharose beads. To assay the activities of different phosphatases these beads were used. Jurkat cells were stimulated with araC for different times and cell extract was prepared. Cells extracts were incubated with different antiphosphatase antibodies followed by immunoprecipitation by protein A/G sepharose. Then these beads were incubated with 32 P-labeled p65 in 20 mm HEPES, pH 7.4, 10 mm MgCl 2 , and 1 mm DTT for 2 h at 371C. Reactions were stopped with the addition of 15 ml of 2 Â SDS sample buffer, boiled for 5 min, and subjected to SDS-PAGE (9%). The gel was dried and 32 P-p65 was analysed by a PhosphorImager (Fuji, Japan).
